NAD+ Price Comparison — Compare 34 Vendors

View full research →
NAD+ / longevity researchSafety Rating 7/10

Price Comparison

Compare vendors · per 500mg

34 vendors competing

VendorPrice$ / mgUpdated
Ascension Peptides8.5/10$29.00$58.00−50% · code peptidepri$0.0580Apr 16, 2026Buy →
Puratek Peptides9.5/10$62.06$68.95−10% · code PEPTIDEPRICES$0.0621May 19, 2026Buy →
PepX7.5/10$75.60$84.00−10% · code PEPTIDEPRICES$0.0756Jun 24, 2026Buy →
Hydro Research9/10$79.20$99.00−20% · code PEPTIDEP20$0.0792Jun 5, 2026Buy →
Axiom Peptides4/10$40.00$0.0800Apr 14, 2026Buy →
Evo Labs Research8/10$84.99$99.99−15% · code JACKR3CCC$0.0850Jun 22, 2026Buy →

Research details

NAD+ — research data

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose range500–1000 mg IV infusion per sessionsource ↗
AdministrationIV infusion (slow, ~2 mg/min over several hours)
Half-lifeRapidly metabolized; tissue effects persist
Safety7/10 · Not FDA-approved (injectable)
NCAA D1Permitted

Overview

About NAD+

Mechanism of action

Coenzyme in redox reactions; activates sirtuins (SIRT1-7) and PARP; critical for mitochondrial function, DNA repair, and cellular energy (ATP) production.

Safety profile

IV: flushing, nausea, headache, chest tightness (infusion-rate dependent). SC: injection site discomfort. Generally safe. · IV widely used in clinics; flushing/nausea common but transient; endogenous molecule; no serious AEs reported

Storage

Stability & handling

❄️Lyophilized (powder)−20°Cprotected from light
💉Reconstituted2–8°Cuse promptly
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Safety & Interactions

Contraindications & Drug Interactions

Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.

! CautionCaution

Chemotherapy — some evidence that high NAD+ may reduce efficacy of certain chemotherapeutics. Avoid during active cancer treatment without oncology guidance.

ℹ NoteCaution

IV infusion rate — rapid infusion causes chest tightness, nausea, anxiety. Slow drip (2-4 hrs) is safer.

ℹ NoteInteraction

PARP inhibitors (olaparib, rucaparib) — NAD+ precursors may counteract therapeutic effect.

Related pages

More on NAD+

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • NAD+ declines ~50% from age 40 to 60 in human whole blood, contributing to impaired sirtuin activity, reduced DNA repair capacity, and mitochondrial dysfunction — the mechanistic basis for NAD+ supplementation research.
  • IV infusion of NAD+ rapidly raises plasma and whole-blood NAD+ metabolome, providing superior bioavailability vs oral precursors for acute repletion.

6 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch